HK1070290A1 - Growth factor complex - Google Patents

Growth factor complex

Info

Publication number
HK1070290A1
HK1070290A1 HK05103080.0A HK05103080A HK1070290A1 HK 1070290 A1 HK1070290 A1 HK 1070290A1 HK 05103080 A HK05103080 A HK 05103080A HK 1070290 A1 HK1070290 A1 HK 1070290A1
Authority
HK
Hong Kong
Prior art keywords
growth factor
insulin
binding protein
protein
vitronectin
Prior art date
Application number
HK05103080.0A
Other languages
English (en)
Inventor
Zee Upton
Jennifer Ann Kricker
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Queensland filed Critical Univ Queensland
Publication of HK1070290A1 publication Critical patent/HK1070290A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
HK05103080.0A 2000-09-22 2005-04-12 Growth factor complex HK1070290A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR0309A AUPR030900A0 (en) 2000-09-22 2000-09-22 Growth factor complex
PCT/AU2001/001196 WO2002024219A1 (fr) 2000-09-22 2001-09-24 Complexe du facteur de croissance

Publications (1)

Publication Number Publication Date
HK1070290A1 true HK1070290A1 (en) 2005-06-17

Family

ID=3824376

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05103080.0A HK1070290A1 (en) 2000-09-22 2005-04-12 Growth factor complex

Country Status (12)

Country Link
US (4) US7514398B2 (fr)
EP (3) EP2385064A3 (fr)
JP (1) JP5165176B2 (fr)
KR (1) KR100898765B1 (fr)
CN (2) CN102940880A (fr)
AU (1) AUPR030900A0 (fr)
CA (1) CA2424394C (fr)
DK (1) DK1333853T3 (fr)
ES (1) ES2392505T3 (fr)
HK (1) HK1070290A1 (fr)
NZ (1) NZ525302A (fr)
WO (1) WO2002024219A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
WO2002060163A2 (fr) * 2000-10-24 2002-08-01 Andress Dennis L Procedes permettant d'augmenter la formation osseuse et de renforcer l'accretion osseuse
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
AU2004208856B2 (en) * 2003-02-05 2009-06-04 Factor Therapeutics Limited Growth factor complexes and modulation of cell migration and growth
US20100143442A1 (en) * 2003-02-05 2010-06-10 Queensland University Of Technology Growth factor complexes and modulation of cell migration and growth
US8871709B2 (en) 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
AU2003903896A0 (en) 2003-07-28 2003-08-07 Queensland University Of Technology Skin regeneration system
ES2341270T3 (es) 2004-12-24 2010-06-17 Insmed, Inc. Complejos rhigf-i/rhigfbp-3 purificados y procedimientos de fabricacion de los mismos.
EP2076589B1 (fr) 2006-10-02 2017-02-22 Orthocell Limited Procédé de fabrication de composants natifs, tels que facteurs de croissance ou protéines de matrice extracellulaire, par mise en culture de cellules d'échantillons de tissu pour la réparation tissulaire
AU2008295441A1 (en) * 2007-09-04 2009-03-12 Queensland University Of Technology A feeder cell-free culture medium and system
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
JP2012522762A (ja) * 2009-04-01 2012-09-27 ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター ケラチノサイトの増殖および分化を調節する方法
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
KR101187814B1 (ko) 2010-03-22 2012-10-08 광주과학기술원 심부전 예방 또는 치료용 약제학적 조성물 및 심부전 예방 또는 치료제의 스크리닝 방법
EP2922862B1 (fr) * 2012-11-22 2019-01-02 Factor Therapeutics Limited Agents de formation-modulation de complexes et leurs utilisations
MX2016006741A (es) * 2013-12-10 2016-08-12 Hoffmann La Roche Uso del dominio de union de una subunidad de una estructura de multiples subunidades para la liberacion dirigida de entidades farmaceuticamente activas a la estructura de multiples subunidades.
JP2017501158A (ja) * 2013-12-18 2017-01-12 ティラビスコ アーベー 嗜好性食品に対する衝動を減らすためのチラコイドの使用
KR101596635B1 (ko) * 2015-05-19 2016-02-23 중앙대학교 산학협력단 Igfbp2를 유효성분으로 함유하는 군날개 예방 또는 치료용 약학조성물
BR112019016250A2 (pt) * 2017-02-06 2020-04-14 Alize Pharma Iii Sas peptídeos isolados, uso do peptídeo isolado, método para prevenção ou tratamento de um distúrbio ósseo, método para melhorar a formação óssea, método para inibir a reabsorção óssea, método para induzir a deposição óssea, método para induzir a maturação óssea, método de expandir células tronco ex vivo e composição farmacêutica
CN107670105B (zh) * 2017-09-29 2018-10-30 中国人民解放军陆军军医大学第一附属医院 Igfbp3在制备骨缺损修复材料中的应用
CA3100665A1 (fr) 2018-05-24 2019-11-28 Amolyt Pharma Domaine de liaison a l'heparine d'igfbp-2 dans le traitement de troubles metaboliques
CN111289756A (zh) * 2018-12-10 2020-06-16 北京师范大学 卵巢癌肺转移成瘤相关的尿液标志物
CN110526958B (zh) * 2019-07-22 2022-04-29 广州暨南大学医药生物技术研究开发中心有限公司 一种活力修复肽Tvigour A及其应用
CN114137214B (zh) * 2021-12-06 2024-03-01 上海市精神卫生中心（上海市心理咨询培训中心） 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275922C (fr) * 1985-11-28 1990-11-06 Harunobu Amagase Traitement du cancer
US5973115A (en) 1987-05-15 1999-10-26 Amgen Inc. Method for potentiating and inhibiting insulin-like growth factor activity
EP0407413B1 (fr) 1988-03-24 1992-06-03 ZACH, Johann Dispositif manometrique ou dynamometrique
WO1990000569A1 (fr) 1988-07-15 1990-01-25 Central Sydney Area Health Service Sous-unite labile aux acides d'un complexe proteique de liaison du facteur de croissance analogue a l'insuline
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5407813A (en) * 1990-05-01 1995-04-18 Gold Biotechnology Preparation of nucleic acid deletion fragments
WO1992001813A1 (fr) 1990-07-25 1992-02-06 Syngene, Inc. Extension circulaire pour generer plusieurs copies complementaires d'un acide nucleique
JPH06503947A (ja) * 1990-08-28 1994-05-12 カイロン　コーポレイション Ｉｇｆｂｐ―５をコードする遺伝物質
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
US5958764A (en) 1992-04-30 1999-09-28 Baylor College Of Medicine Specific expression vectors and methods of use
AU4238493A (en) * 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
WO1994018232A1 (fr) 1993-02-12 1994-08-18 Repligen Corporation Procedes de generation d'anticorps anti-vih a large spectre de neutralisation et antigenes capables de provoquer la generation de ces anticorps
WO1994022466A1 (fr) * 1993-04-07 1994-10-13 Synergen, Inc. Procedes d'utilisation de proteines de liaison de facteurs de croissance semblables a l'insuline
EP0619314A1 (fr) * 1993-04-09 1994-10-12 Eli Lilly And Company Dérivés de 4-phényl-4H-naphtho 2,1-b pyran et leur utilisation pharmaceutique
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
AU7096194A (en) * 1993-06-01 1994-12-20 Ludwig Institute For Cancer Research Fragments of neurofibromin (nf1) and method to reverse activated ras induced malignant transformation in mammalian cells
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
JP3974941B2 (ja) 1995-11-21 2007-09-12 イェール ユニバーシティ 単分子セグメントの増幅および検出
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
WO1998024922A1 (fr) * 1996-12-02 1998-06-11 Valentis, Inc. Systeme d'expression du facteur de croissance insulinoide i (igf-i) et ses methodes d'utilisation
US5914390A (en) * 1997-05-12 1999-06-22 Celtrix Pharmaceuticals, Inc. Methods for increasing yields of recombinant proteins
US6077987A (en) 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
AU3192299A (en) 1998-03-18 1999-10-11 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
AUPP298498A0 (en) 1998-04-17 1998-05-07 Gropep Pty Ltd Matrix binding factor
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
ATE303159T1 (de) * 1998-10-02 2005-09-15 Celtrix Pharma Null igf zur krebsbehandlung
AU6515499A (en) 1998-10-16 2000-05-08 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU3897200A (en) * 1999-03-18 2000-10-04 Hope Heart Institute, The Endothelial cell stimulation by a complex of fibronectin and vascular endothelial growth factor
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex

Also Published As

Publication number Publication date
US20070243226A1 (en) 2007-10-18
JP5165176B2 (ja) 2013-03-21
US20040049017A1 (en) 2004-03-11
EP2385064A2 (fr) 2011-11-09
CN1541107B (zh) 2013-03-20
US7785835B2 (en) 2010-08-31
US20140045749A1 (en) 2014-02-13
KR100898765B1 (ko) 2009-05-20
CA2424394A1 (fr) 2002-03-28
DK1333853T3 (da) 2012-11-05
WO2002024219A1 (fr) 2002-03-28
EP2385064A3 (fr) 2012-02-29
CN1541107A (zh) 2004-10-27
EP1333853B1 (fr) 2012-08-01
JP2004510711A (ja) 2004-04-08
US7514398B2 (en) 2009-04-07
EP2385063A3 (fr) 2012-02-29
EP1333853A1 (fr) 2003-08-13
NZ525302A (en) 2005-02-25
EP2385063A2 (fr) 2011-11-09
EP1333853A4 (fr) 2008-03-26
ES2392505T3 (es) 2012-12-11
KR20030063344A (ko) 2003-07-28
US8933027B2 (en) 2015-01-13
US20100279927A1 (en) 2010-11-04
CN102940880A (zh) 2013-02-27
CA2424394C (fr) 2017-05-23
US8563507B2 (en) 2013-10-22
AUPR030900A0 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
HK1070290A1 (en) Growth factor complex
ATE469654T1 (de) Verwendung des erythropoietins zur regeneration von lebergewebe
HK1136480A1 (en) Solid dressing for treating wounded tissue
IL113423A0 (en) Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo utilizing amphipathic peptides and compositions therefor
HK1091216A1 (en) Growth factor complexes and modulation of cell migration and growth
WO1999038952A3 (fr) Cellules ou tissus avec facteurs proteiques en quantite accrue et leurs methodes d'obtention et d'utilisation
DE69132823D1 (de) Knochen- und knorpel-bildung hervorrufende proteine
WO2000056297A3 (fr) Compositions favorisant la croissance
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
MXPA03005742A (es) Combinacion de un estrogeno y un androgeno para tratar deficiencias hormonales en mujeres que sufren terapia de reemplazo de estrogenos.
HK1071525A1 (en) Method and composition for treating skin wounds with epidermal growth factor
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
WO2003095637B1 (fr) Combinaison d'un facteur de croissance et d'une enzyme protease
PT661990E (pt) Metodo para tratamento sistemico de condicoes catabolicas e de lesoes sistemicas em tecidos
IL144523A0 (en) Method and compositions for healing and repair of articular cartilage
Kruse et al. Evaluation of the efficacy of cell and micrograft transplantation for full-thickness wound healing
Boggio et al. Is there an easier way to autograft skin in chronic leg ulcers?‘Minced micrografts’, a new technique
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE69920015D1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
ATE526945T1 (de) Verfahren zur erhöhung von fibronectin
Nilforoushzadeh et al. Treatment of recalcitrant electrical burn ulcer with application of topical trichloroacetic acid and autologous cultured fibroblast
ATE253945T1 (de) Verwendung von wundverbänden zur behandlung von akuten wunden
UA41861A (uk) Спосіб лікування ран, що довго не загоюються
ATE448809T1 (de) Biomaterial auf der basis von hyaluronsäurebenzylester zur antiangiogenen therapie in der tumorbehandlung

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190924